PPD Establishes Network of Sites for Conducting Phase I Trials
WILMINGTON, N.C.,
(September 7, 2010) -
PPD
, Inc. announced it has established preferred provider relationships with a network of sites across North America for conducting Phase I trials in patients to meet growing client demand for these services. PPD has established relationships with Commonwealth Biomedical Research in Madisonville, Ky., CNS Network in Los Angeles and Lovelace Scientific Resources, a wholly-owned subsidiary of Lovelace Respiratory Research, in Albuquerque, N.M., Austin, Texas, and Sarasota, Fla. The relationships increase PPD's ability to recruit patients for Phase I trials across a broad range of therapeutic areas, including cardiovascular, metabolic, respiratory, central nervous system, renal/hepatic disease and biologics. It also strengthens the company's ability to deliver clients an integrated offering that spans preclinical, Phase I, data management and Phase II-IV clinical development and monitoring services. "Patient volunteers currently account for approximately 40 percent of all participants in Phase I studies," said Cindy Doerfler, vice president of PPD's Phase I clinic. "By choosing to build relationships with sites that have demonstrated superior quality and the ability to recruit for various patient populations, we provide our clients a very flexible model for patient enrollment, site location and therapeutic expertise." Expanding its Phase I services allows PPD to work even more closely with clients in determining early proof-of-concept for compounds and biosimilars where drugs must go directly into patients. The company is hiring senior project managers in North America who will oversee the development of its networks and manage Phase I trials conducted through the sites. It plans to implement this model in other regions such as Central and Eastern Europe and Asia-Pacific. PPD already operates a 300-bed Phase I healthy volunteer clinic in
Austin, Texas
, which is one of the largest in the world.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
